MX2020008063A - Nuevos usos. - Google Patents

Nuevos usos.

Info

Publication number
MX2020008063A
MX2020008063A MX2020008063A MX2020008063A MX2020008063A MX 2020008063 A MX2020008063 A MX 2020008063A MX 2020008063 A MX2020008063 A MX 2020008063A MX 2020008063 A MX2020008063 A MX 2020008063A MX 2020008063 A MX2020008063 A MX 2020008063A
Authority
MX
Mexico
Prior art keywords
novel uses
norclozapine
prodrugs
solvates
prevention
Prior art date
Application number
MX2020008063A
Other languages
English (en)
Inventor
Duncan Mchale
Stephen Jolles
Houman Ashrafian
Original Assignee
Zarodex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zarodex Therapeutics Ltd filed Critical Zarodex Therapeutics Ltd
Publication of MX2020008063A publication Critical patent/MX2020008063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere al compuesto clozapina, y su metabolito principal norclozapina y profarmacos de las mismas y sales y solvatos farmaceuticamente aceptables de las mismas para su uso en el tratamiento o prevención de una enfermedad de células B impulsada por inmunoglobulina patógena; la invención también proporciona composiciones farmacéuticas que contienen dichos compuestos.
MX2020008063A 2018-01-31 2019-01-31 Nuevos usos. MX2020008063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154553.4A EP3520803A1 (en) 2018-01-31 2018-01-31 Novel uses
PCT/EP2019/052449 WO2019149861A1 (en) 2018-01-31 2019-01-31 Novel uses

Publications (1)

Publication Number Publication Date
MX2020008063A true MX2020008063A (es) 2020-12-03

Family

ID=61192666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008063A MX2020008063A (es) 2018-01-31 2019-01-31 Nuevos usos.

Country Status (10)

Country Link
US (1) US20210236513A1 (es)
EP (2) EP3520803A1 (es)
JP (1) JP2021512872A (es)
KR (1) KR20200115490A (es)
CN (1) CN111836633A (es)
AU (1) AU2019216379A1 (es)
CA (1) CA3086463A1 (es)
MX (1) MX2020008063A (es)
SG (1) SG11202005711TA (es)
WO (1) WO2019149861A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910873D0 (en) * 2019-07-30 2019-09-11 Zarodex Therapeutics Ltd Novel uses
WO2021068203A1 (zh) * 2019-10-11 2021-04-15 中山大学附属第一医院 一种氯喹或衍生物羟氯喹的用途
AU2021205502A1 (en) * 2020-01-10 2022-07-21 Coimmune, Inc. Methods of treating tumors
WO2021211923A1 (en) * 2020-04-16 2021-10-21 Pulmoquine Therapeutics, Inc. Compositions and methods for treating disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CN1329490A (zh) * 1998-10-09 2002-01-02 先灵公司 用于治疗变应性疾病的组合物和方法
JP2006522811A (ja) * 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
US20100168085A1 (en) * 2003-05-22 2010-07-01 Yesa Research And Development Co. Ltd. At The Weizmann Institute Of Science Dopamine and agonists and antagonists thereof for modulation of suppressive activity of CD4+CD25+ regulatory T cells
ITMI20042232A1 (it) 2004-11-19 2005-02-19 Unihart Corp Composizione farmaceutica contenente clozapina
US20070299043A1 (en) * 2005-10-03 2007-12-27 Hunter William L Anti-scarring drug combinations and use thereof
AU2008279636A1 (en) * 2007-07-25 2009-01-29 The Regents Of The University Of Colorado Central administration of stable formulations of therapeutic agents for CNS conditions
CN104193741B (zh) * 2007-10-01 2016-08-24 阿尔法梅根有限责任公司 作为α7-烟碱乙酰胆碱受体配体的奎宁环-4-基甲基1H-吲哚-3-甲酸酯衍生物
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
WO2011041687A1 (en) * 2009-10-02 2011-04-07 Stern R Gabriel Methods of treating sialorrhea with bupropion and its metabolites
EP2588112B1 (en) * 2010-06-30 2017-09-27 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Also Published As

Publication number Publication date
KR20200115490A (ko) 2020-10-07
EP3520803A1 (en) 2019-08-07
US20210236513A1 (en) 2021-08-05
SG11202005711TA (en) 2020-07-29
CA3086463A1 (en) 2019-08-08
JP2021512872A (ja) 2021-05-20
WO2019149861A1 (en) 2019-08-08
CN111836633A (zh) 2020-10-27
AU2019216379A1 (en) 2020-06-25
EP3746108A1 (en) 2020-12-09

Similar Documents

Publication Publication Date Title
MX2020008063A (es) Nuevos usos.
JOP20190229B1 (ar) مركبات تثبط بروتين mcl-1
PH12018501920B1 (en) Bromodomain inhibitors
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
MX2020008060A (es) Clozapina para el tratamiento de una enfermedad de celulas b impulsada por inmunoglobulina.
PH12020550616A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
ZA202204442B (en) Salt forms of a complement component c5a receptor
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
JOP20190054B1 (ar) مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
PH12017501668A1 (en) Bace1 inhibitors
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
PH12020500120A1 (en) Pharmaceutical compositions
MX2020006472A (es) Derivados de glucosamina para la prevencion o tratamiento de trastornos articulares.
MA39901A (fr) Antagonistes de mglu2/3 pour le traitement de troubles des facultés intellectuelles
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
EA201992754A1 (ru) Фармацевтические композиции